To compile the report, Moody’s analyzed data drug companies presented at the American Society of Clinical Oncology meeting held June 3 to June 7 in Chicago.
Here are four report findings.
- Moody’s predicts breast cancer and lung cancer will be the largest drivers of sales growth in 2017 and 2018.
- Merck, AstraZeneca, Eli Lilly and Incyte Corp., will benefit the most from this growth, according to the report.
- Roche, Pfizer and Bristol-Myers Squibb will experience increasing competitive pressures in the future cancer drug market. However, these drugmakers will still benefit from ongoing development of new oncology treatments.
- Combination regimens will grow into increasingly important drug therapies.
More articles on supply chain:
Across enemy lines: Insurer recruits former drug reps to push more generics
Joslin Diabetes Center affiliate HSHS Medical Group to offer MiniMed insulin pump
FDA OKs Claret Medical’s stroke prevention device
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
